Shares of Geron GERN are higher on the session by 11.24%, currently trading at $2.97. The stock has been moving largely lower over the past three months and is currently trading below the 50-day moving average.
Options traders are focusing on calls today. A short while ago the October 2011 $3.00 call traded 800 times on open interest of 149 contracts.
Calls are outpacing puts today by 50 to 1.
Geron Corporation is developing biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. Geron is engaged in the discovery and development of therapeutic and diagnostic products for oncology and human embryonic stem cell therapies.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Options
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in